ADCs: Bridging the East-West Divide

The antibody-drug conjugates (ADCs) field is experiencing rapid global growth, with notable advancements in both the West and the East. Countries like China, Japan, and South Korea are emerging as key players in the ADC landscape. However, there is a gap in the Western biopharma community’s engagement with Eastern markets, presenting both risks and opportunities. This report delves into the status, opportunities, and considerations of ADC development, focusing on bridging the gap between the East and West.

Key highlights include:

• Overview of the current global ADC drug and developer landscape, with a discussion on the significant shift in ADC activity in the East.
• Examination of innovation and intellectual property status in the East, including implications for Western companies.
• Analysis of global ADC approvals, with a discussion on the growing role of Eastern regulatory bodies and considerations for engaging in these environments.
• Overview of global ADC deals and collaborations, addressing the benefits and concerns affecting these collaborations.